research

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Authors
Publication date
1 January 2018
Publisher
Digital Commons@Becker

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Digital Commons@Becker

    redirect
    oaioai:digitalcommons.wustl.edu:o...
    Last time updated on 09/07/2019